<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="which is the main reason for their toxicity [10]. 2.1." exact="Zidovudine" post="Zidovudine (3′-azido-2′,3′-dideoxythymidine, AZT) was first synthesized in the 1960s"/>
 <result pre="is the main reason for their toxicity [10]. 2.1. Zidovudine" exact="Zidovudine" post="(3′-azido-2′,3′-dideoxythymidine, AZT) was first synthesized in the 1960s [11]"/>
 <result pre="for treatment of HIV infection [13]. The anti-FIV activity of" exact="zidovudine" post="has been assessed in numerous in vitro studies in"/>
 <result pre="carried out in 1989, when North and coworkers showed that" exact="zidovudine" post="inhibited FIV replication in Crandell-Rees feline kidney (CRFK) cells."/>
 <result pre="Crandell-Rees feline kidney (CRFK) cells. The susceptibility of FIV to" exact="zidovudine" post="was similar to that of HIV [27]. There is"/>
 <result pre="the FIV gene is responsible for resistance [10]. In vivo," exact="zidovudine" post="can reduce plasma viral load, improve the immunologic and"/>
 <result pre="of life, and prolong life expectancy [16]. In placebo-controlled trials," exact="zidovudine" post="improved stomatitis and increased the CD4/CD8 ratio in naturally"/>
 <result pre="improvement was reported within the first days of therapy [28,29]." exact="Zidovudine" post="not only inhibits RT, but also cellular polymerases, and"/>
 <result pre="bone marrow suppression. Regular blood cell counts are necessary during" exact="zidovudine" post="treatment because non-regenerative anemia is a common side effect"/>
 <result pre="not be treated with zidovudine. Most FIV-infected cats treated with" exact="zidovudine" post="for as long as two years tolerated the drug"/>
 <result pre="in cats, including vomiting or anorexia, are rare [28]. 2.2." exact="Stavudine" post="Stavudine (2′,3′-didehydro-2′,3′-dideoxythymidine, d4T) is another drug effective against HIV."/>
 <result pre="cats, including vomiting or anorexia, are rare [28]. 2.2. Stavudine" exact="Stavudine" post="(2′,3′-didehydro-2′,3′-dideoxythymidine, d4T) is another drug effective against HIV. It"/>
 <result pre="multi-drug treatment protocols by compounds with fewer side effects [30,31,32,33,34]." exact="Stavudine" post="is active against FIV in vitro [18,19,20,23,26,35,36]. Mutants of"/>
 <result pre="in vitro [18,19,20,23,26,35,36]. Mutants of FIV that are resistant to" exact="stavudine" post="and cross-resistant to several other antivirals, including zidovudine, have"/>
 <result pre="contributed to the development of antiretroviral toxic neuropathy [39]. 2.4." exact="Lamivudine" post="Lamivudine (2R,cis-4-amino-l-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, 3TC) is also an anti-HIV drug, approved"/>
 <result pre="to the development of antiretroviral toxic neuropathy [39]. 2.4. Lamivudine" exact="Lamivudine" post="(2R,cis-4-amino-l-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, 3TC) is also an anti-HIV drug, approved in"/>
 <result pre="3TC) is also an anti-HIV drug, approved in 1995 [40]." exact="Lamivudine" post="is active against FIV in vitro [3,20,21,23,38,41]. A combination"/>
 <result pre="is active against FIV in vitro [3,20,21,23,38,41]. A combination of" exact="zidovudine" post="and lamivudine had synergistic anti-FIV activities in cell cultures"/>
 <result pre="against FIV in vitro [3,20,21,23,38,41]. A combination of zidovudine and" exact="lamivudine" post="had synergistic anti-FIV activities in cell cultures [41]. FIV"/>
 <result pre="anti-FIV activities in cell cultures [41]. FIV mutants resistant to" exact="lamivudine" post="and containing a point mutation in the RT gene"/>
 <result pre="gene were selected in vitro and showed cross resistance to" exact="zidovudine" post="[23]. In one in vivo study, experimentally FIV-infected cats"/>
 <result pre="the cats with this high-dose dual-drug treatment [41]. Thus, high-dose" exact="lamivudine" post="treatment alone, or in combination with zidovudine, is not"/>
 <result pre="with zidovudine, is not recommended in naturally FIV-infected cats. 2.5." exact="Emtricitabine" post="Emtricitabine (2',3'-deoxy-5-fluoro-3'-thiacytidine, FTC) is structurally similar to lamivudine and"/>
 <result pre="zidovudine, is not recommended in naturally FIV-infected cats. 2.5. Emtricitabine" exact="Emtricitabine" post="(2',3'-deoxy-5-fluoro-3'-thiacytidine, FTC) is structurally similar to lamivudine and was"/>
 <result pre="cats. 2.5. Emtricitabine Emtricitabine (2',3'-deoxy-5-fluoro-3'-thiacytidine, FTC) is structurally similar to" exact="lamivudine" post="and was licensed by the FDA in 2003 [40]."/>
 <result pre="have been no in vivo studies in FIV-infected cats. 2.6." exact="Abacavir" post="Abacavir ((1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, ABC) was shown to be active against"/>
 <result pre="been no in vivo studies in FIV-infected cats. 2.6. Abacavir" exact="Abacavir" post="((1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, ABC) was shown to be active against HIV"/>
 <result pre="in 1986 and belongs to the FDA-approved anti-HIV compounds [40]." exact="Abacavir" post="is active against FIV in vitro, but had higher"/>
 <result pre="had higher levels of cytotoxicity than other compounds, such as" exact="didanosine" post="and amdoxovir [16,20]. There are no in vivo studies"/>
 <result pre="and necessity for continuous intravenous administration of the drug. 5.2." exact="Ribavirin" post="Ribavirin (1-β- d-ribofuranosyl-1 H-1,2,4-triazole-3-carboxamide, RTCA) has marked in vitro"/>
 <result pre="necessity for continuous intravenous administration of the drug. 5.2. Ribavirin" exact="Ribavirin" post="(1-β- d-ribofuranosyl-1 H-1,2,4-triazole-3-carboxamide, RTCA) has marked in vitro antiviral"/>
 <result pre="variety of DNA and RNA viruses [71]. Systemic administration of" exact="ribavirin" post="is limited in cats because of side effects [72]."/>
 <result pre="limited in cats because of side effects [72]. Sequestration of" exact="ribavirin" post="within erythrocytes results in hemolysis, even when low doses"/>
 <result pre="primarily on megakaryocytes, resulting in thrombocytopenia and hemorrhage. With prolonged" exact="ribavirin" post="treatment or at higher doses, the production of erythrocytes"/>
 <result pre="doses, the production of erythrocytes and neutrophils also is suppressed." exact="Ribavirin" post="also can induce hepatic toxicity. An attempt to decrease"/>
 <result pre="induce hepatic toxicity. An attempt to decrease the toxicity of" exact="ribavirin" post="by incorporating it into lecithin-containing liposomes and administering it"/>
 <result pre="and administering it at lower doses was not successful [75]." exact="Ribavirin" post="is active against many viruses in vitro, including FIV"/>
 <result pre="vivo because of toxicity [74]. To date, the efficacy of" exact="ribavirin" post="has not been investigated in FIV-infected cats. 6. Receptor"/>
 <result pre="active site of the protease have been developed [85,86,87]. 7.1." exact="Tipranavir" post="Tipranavir (N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propy l]phenyl]-5-(trifluoromethyl)pyridin-2-sulfonamid) was approved in 2005, and is"/>
 <result pre="site of the protease have been developed [85,86,87]. 7.1. Tipranavir" exact="Tipranavir" post="(N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propy l]phenyl]-5-(trifluoromethyl)pyridin-2-sulfonamid) was approved in 2005, and is used"/>
 <result pre="and further studies are needed to investigate the potential of" exact="tipranavir" post="in naturally infected cats. 7.2. Lopinavir Lopinavir (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhex-an-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide) is"/>
 <result pre="There are no in vivo studies in FIV-infected cats. 7.3." exact="Atazanavir" post="Atazanavir (methyl N-[(2R)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2R)-2-(methoxycarbonylamino)-3,3-di-methylbutanoyl]amino]-4-(2,3,4,5,6-pentadeuteriophenyl)butyl]-2-[(4-pyridin-2-ylphenyl)methyl]hy-drazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate) was licensed by the FDA in"/>
 <result pre="are no in vivo studies in FIV-infected cats. 7.3. Atazanavir" exact="Atazanavir" post="(methyl N-[(2R)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2R)-2-(methoxycarbonylamino)-3,3-di-methylbutanoyl]amino]-4-(2,3,4,5,6-pentadeuteriophenyl)butyl]-2-[(4-pyridin-2-ylphenyl)methyl]hy-drazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate) was licensed by the FDA in 2003"/>
 <result pre="as an anti-HIV compound. Similar to lopinavir, some efficacy of" exact="atazanavir" post="was shown against FIV in vitro, but there are"/>
 <result pre="Author’s Personal Opinion Ebm Level (I–Iv) Nucleoside Analogue—Reverse Transcriptase Inhibitors" exact="Zidovudine" post="(AZT) yes [27,14,16,17,18,19,20,22,23,24,25,26,38] yes [76,28,29] effective in some cats"/>
 <result pre="effective in some cats (e.g., with stomatitis, neurological disorders) I" exact="Stavudine" post="(d4T) yes [14,18,20,21,22,23,26,76] nd possibly effective, but no data"/>
 <result pre="effective in one experimental study, but neurologic side effects II" exact="Zalcitabine" post="(ddC) yes [14,15,17,19,21,22,23,26,47] nd possibly effective, but toxic IV"/>
 <result pre="Zalcitabine (ddC) yes [14,15,17,19,21,22,23,26,47] nd possibly effective, but toxic IV" exact="Lamivudine" post="(3TC) yes [16,17,20,21,22,23,76] no [41] not very effective, toxic"/>
 <result pre="no [41] not very effective, toxic in high dosages II" exact="Emtricitabine" post="(FTC) yes [17,20,21,22] nd possibly effective, but no data"/>
 <result pre="nd possibly effective, but no data in cats available IV" exact="Abacavir" post="(ABC) yes [20] nd possibly effective but toxic IV"/>
 <result pre="yes [14] nd effective in vitro, but too toxic IV" exact="Ribavirin" post="yes [23,76] nd possibly effective, but too toxic in"/>
 <result pre="cats (thus, can be considered as treatment) I Protease Inhibitors" exact="Tipranavir" post="yes [85] nd potentially effective, but no in vivo"/>
 <result pre="data available IV Lopinavir yes [85] nd likely ineffective IV" exact="Atazanavir" post="yes [85] nd likely ineffective IV Integrase Inhibitors Raltegravir"/>
 <result pre="feline immunodeficiency virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of" exact="zidovudine" post="(ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in"/>
 <result pre="virus infection: Part 1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine (ZDV)," exact="lamivudine" post="(3TC) and abacavir (ABC) antiretroviral therapy in suppressing in"/>
 <result pre="1Feline Pract1995231621 16.BissetL.R.LutzH.BoniJ.Hofmann-LehmannR.LuthyR.SchupbachJ.Combined effect of zidovudine (ZDV), lamivudine (3TC) and" exact="abacavir" post="(ABC) antiretroviral therapy in suppressing in vitro FIV replicationAntivir."/>
 <result pre="inhibitors for the treatment of HIV: A brief history of" exact="stavudine" post="(D4T) and its comparison with other dideoxynucleosidesAntivir. Res.201085343810.1016/j.antiviral.2009.10.00619854224 35.BalzariniJ.EgberinkH.HartmannK.CahardD.VahlenkampT.ThormarH.de"/>
 <result pre="FIV infected catsTierarztliche Praxis Ausgabe K, Kleintiere/Heimtiere1997256716779459835 52.PhilpottM.S.EbnerJ.P.HooverE.A.Evaluation of 9-(2-phosphonylmethoxyethyl)" exact="adenine" post="therapy for feline immunodeficiency virus using a quantitative polymerase"/>
 <result pre="kinetic analysesProtein Sci.2007161728173710.1110/ps.07282900717656585 56.DasK.MartinezS.E.BaumanJ.D.ArnoldE.HIV-1 reverse transcriptase complex with DNA and" exact="nevirapine" post="reveals non-nucleoside inhibition mechanismNat. Struct. Mol. Biol.20121925325910.1038/nsmb.222322266819 57.AuwerxJ.NorthT.W.PrestonB.D.KlarmannG.J.De ClercqE.BalzariniJ.Chimeric"/>
 <result pre="multiple effects on virus replication and propagation. Molecular basis of" exact="ribavirin" post="resistanceCurr. Opin. Virol.20148101510.1016/j.coviro.2014.04.01124846716 72.LafeuilladeA.HittingerG.ChadapaudS.Increased mitochondrial toxicity with ribavirin in"/>
 <result pre="basis of ribavirin resistanceCurr. Opin. Virol.20148101510.1016/j.coviro.2014.04.01124846716 72.LafeuilladeA.HittingerG.ChadapaudS.Increased mitochondrial toxicity with" exact="ribavirin" post="in HIV/HCV coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered ribavirin on"/>
 <result pre="toxicity with ribavirin in HIV/HCV coinfectionLancet200135728028110.1016/S0140-6736(00)03618-711214134 73.PoveyR.C.Effect of orally administered" exact="ribavirin" post="on experimental feline calicivirus infection in catsAm. J. Vet."/>
 <result pre="calicivirus infection in catsAm. J. Vet. Res.19783913371341697143 74.WeissR.C.CoxN.R.BoudreauxM.K.Toxicologic effects of" exact="ribavirin" post="in catsJ. Vet. Pharmacol. Ther.19931630131610.1111/j.1365-2885.1993.tb00177.x8230401 75.WeissR.C.CoxN.R.MartinezM.L.Evaluation of free or"/>
 <result pre="in catsJ. Vet. Pharmacol. Ther.19931630131610.1111/j.1365-2885.1993.tb00177.x8230401 75.WeissR.C.CoxN.R.MartinezM.L.Evaluation of free or liposome-encapsulated" exact="ribavirin" post="for antiviral therapy of experimentally induced feline infectious peritonitisRes."/>
 <result pre="antagonistBlood20031022728273010.1182/blood-2003-02-066312855591 85.NorelliS.El DakerS.D’OstilioD.MeleF.ManciniF.TagliaF.RuggieriA.CiccozziM.CaudaR.CiervoA.et al.Response of feline immunodeficiency virus (FIV) to" exact="tipranavir" post="may provide new clues for development of broad-based inhibitors"/>
 <result pre="type-I interferon on retrovirusesViruses2009154557310.3390/v103054521994560 100.ZeidnerN.S.MylesM.H.Mathiason-DuBardC.K.DreitzM.J.MullinsJ.I.HooverE.A.Alpha interferon (2β) in combination with" exact="zidovudine" post="for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency"/>
</results>
